Nothing Special   »   [go: up one dir, main page]

MX2023002648A - Mutante de il-2 y aplicacion de este. - Google Patents

Mutante de il-2 y aplicacion de este.

Info

Publication number
MX2023002648A
MX2023002648A MX2023002648A MX2023002648A MX2023002648A MX 2023002648 A MX2023002648 A MX 2023002648A MX 2023002648 A MX2023002648 A MX 2023002648A MX 2023002648 A MX2023002648 A MX 2023002648A MX 2023002648 A MX2023002648 A MX 2023002648A
Authority
MX
Mexico
Prior art keywords
mutant
fusion protein
compared
application
increases
Prior art date
Application number
MX2023002648A
Other languages
English (en)
Inventor
Yayuan Fu
Zhuoxiao Cao
Hu Ge
Renhong Tang
Jinsheng Ren
Yingying Hu
Original Assignee
Shandong Simcere Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Simcere Biopharmaceutical Co Ltd filed Critical Shandong Simcere Biopharmaceutical Co Ltd
Publication of MX2023002648A publication Critical patent/MX2023002648A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente divulgación describe mutantes de IL-2 y usos de estos. Más específicamente, la divulgación proporciona mutantes de IL-2 y proteínas de fusión correspondientes, conjugados, fragmentos de ácido nucleico, vectores, células hospedadoras, métodos para preparar los mutantes o proteínas de fusión, mutantes de IL-2 o proteínas de fusión que se preparan de acuerdo con los métodos, composiciones farmacéuticas, usos farmacéuticos, métodos para tratar enfermedades y métodos para estimular preferentemente los linfocitos T reguladores. En comparación con la IL-2 no modificada, los mutantes de IL-2 de la presente divulgación tienen valores de Tm más altos y una estabilidad mejorada; como alternativa, los mutantes de IL-2 de la presente divulgación tienen un mayor rendimiento o una actividad de unión modificada a los complejos IL-2Rß? en comparación con la IL-2 no modificada.
MX2023002648A 2020-09-04 2021-09-03 Mutante de il-2 y aplicacion de este. MX2023002648A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010918842 2020-09-04
CN202110932286 2021-08-13
PCT/CN2021/116463 WO2022048640A1 (zh) 2020-09-04 2021-09-03 Il-2突变体及其应用

Publications (1)

Publication Number Publication Date
MX2023002648A true MX2023002648A (es) 2023-04-05

Family

ID=80490673

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002648A MX2023002648A (es) 2020-09-04 2021-09-03 Mutante de il-2 y aplicacion de este.

Country Status (13)

Country Link
US (3) US20230265148A1 (es)
EP (1) EP4209503A4 (es)
KR (1) KR20230061490A (es)
CN (1) CN116323653A (es)
AU (1) AU2021338393B2 (es)
BR (1) BR112023004040A2 (es)
CA (1) CA3191260A1 (es)
CL (1) CL2023000631A1 (es)
IL (1) IL301027A (es)
MX (1) MX2023002648A (es)
PE (1) PE20240123A1 (es)
WO (1) WO2022048640A1 (es)
ZA (1) ZA202304098B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023227283A1 (en) * 2022-03-03 2024-09-19 Hainan Simcere Pharmaceutical Co., Ltd. Pharmaceutical composition of il2 mutant-antibody fc block fusion protein and use thereof
WO2023245097A2 (en) * 2022-06-16 2023-12-21 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
WO2023241653A1 (zh) * 2022-06-17 2023-12-21 舒泰神（北京）生物制药股份有限公司 白介素-2(il-2)突变体及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1208345C (zh) * 2002-07-23 2005-06-29 重庆大学 重组人白细胞介素－2的三突变体及制备方法
CU23734A1 (es) * 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
WO2014023679A1 (en) * 2012-08-07 2014-02-13 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
CN104231068A (zh) * 2014-01-27 2014-12-24 苏州发士达生物科技有限公司 人白细胞介素ii突变体及其应用
US20210260163A1 (en) * 2018-03-09 2021-08-26 AskGene Pharma, Inc. Novel cytokine prodrugs
SG11202102777PA (en) * 2018-09-27 2021-04-29 Xilio Development Inc Masked cytokine polypeptides

Also Published As

Publication number Publication date
KR20230061490A (ko) 2023-05-08
JP2023540761A (ja) 2023-09-26
PE20240123A1 (es) 2024-01-22
EP4209503A1 (en) 2023-07-12
CA3191260A1 (en) 2022-03-10
US20240247041A1 (en) 2024-07-25
CN116323653A (zh) 2023-06-23
WO2022048640A1 (zh) 2022-03-10
CL2023000631A1 (es) 2023-10-13
TW202214677A (zh) 2022-04-16
ZA202304098B (en) 2023-09-27
US20230265148A1 (en) 2023-08-24
US20240209051A1 (en) 2024-06-27
EP4209503A4 (en) 2024-08-21
AU2021338393A1 (en) 2023-05-11
BR112023004040A2 (pt) 2023-04-04
IL301027A (en) 2023-05-01
AU2021338393B2 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
MX2023002648A (es) Mutante de il-2 y aplicacion de este.
JP2023164900A5 (es)
US20180271891A1 (en) Selective treatment of prmt5 dependent cancer
JP2021176866A (ja) 共通ネオ抗原
EP3352782B1 (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
RS20100555A (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
UA104890C2 (uk) Антитіла проти фактора росту нервів (фрн), що мають підвищену стабільність in vivo
Hong et al. Effect of sodium butyrate on the assembly, charge variants, and galactosylation of antibody produced in recombinant Chinese hamster ovary cells
WO2012075173A3 (en) Compositions and method for deimmunization of proteins
US20190161543A1 (en) Modulation of afucosylated species in a monoclonal antibody composition
WO2022089605A1 (en) Modified red blood cells and uses thereof for delivering agents
WO2019241893A3 (en) Anti-her3 antibody and uses thereof
MX2020012499A (es) Compuestos heterocondensados de piridonas y su uso como inhibidores de la idh.
BR112021019570A2 (pt) Proteína de fusão, imunoconjugado, ácido nucleico isolado, vetor, célula, composição, uso dos mesmos para tratar um tumor, bem como métodos para preparar a proteína de fusão, para bloquear a interação entre a proteína pd-l1 e pd-1 e entre cd47 e sirp-alfa e para inibir o crescimento e/ou proliferação de tumores ou células tumorais
CN114457110A (zh) 一种敲除fut8基因的方法
WO2021133959A3 (en) Compositions and methods for gamma delta tcr reprogramming using fusion proteins
Reinhart et al. Differential gene expression of a feed-spiked super-producing CHO cell line
WO2005119251A3 (en) Novel means and methods for the treatment of hearing loss and phantom hearing
WO2023049636A3 (en) Cancer therapy compositions and uses thereof
US20190048070A1 (en) Reduction of high molecular weight species, acidic charge species and fragments in a monoclonal antibody composition
Godfrey et al. Polysome profiling of mAb producing CHO cell lines links translational control of cell proliferation and recombinant mRNA loading onto ribosomes with global and recombinant protein synthesis
NO20055209L (no) Peptabody for cancerbehandling
CN105218682A (zh) 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途
Meunier et al. Synergistic CD40 signaling on APCs and CD8 T cells drives efficient CD8 response and memory differentiation
US20220016191A1 (en) Simultaneous delivery of cancer treatment programs to tumor and immune cells